Evidence map›Paper›PMID 31350556›Full record

ArticleNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2020

Economic Evaluation of Five Tobacco Control Policies Across Seven European Countries.

Teresa Leão, Julian Perelman, Luke Clancy, Martin Mlinarić, Jaana M Kinnunen, Paulien A W Nuyts, Nora Mélard, Arja Rimpelä, Vincent Lorant, Anton E Kunst

Open access · bronzeAbstract readEvaluation Study
In one paragraph

Article in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 6 countries.

Teresa LeãoEscola Nacional de Saúde Pública, Universidade NOVA de Lisboa, Lisboa, Portugal.
Julian PerelmanEscola Nacional de Saúde Pública, Universidade NOVA de Lisboa, Lisboa, Portugal.
Luke ClancyTobaccoFree Research Institute Ireland, Dublin, Ireland.
Martin MlinarićInstitute of Medical Sociology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle, Germany.
Jaana M KinnunenUnit of Health Sciences, Faculty of Social Sciences, Tampere University, Tampere, Finland.
Paulien A W NuytsAmsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Nora MélardInstitute of Health and Society, Université catholique de Louvain, Brussels, Belgium.
Arja RimpeläUnit of Health Sciences, Faculty of Social Sciences, Tampere University, Tampere, Finland.
Vincent LorantInstitute of Health and Society, Université catholique de Louvain, Brussels, Belgium.
Anton E KunstAmsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Amsterdam University Medical Centers · NLTampere University · FIUCLouvain · BEUniversidade Nova de Lisboa · PTMartin Luther University Halle-Wittenberg · DETobaccoFree Research Institute · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionEconomic evaluations of tobacco control policies targeting adolescents are scarce. Few take into account real-world, large-scale implementation costs; few compare cost-effectiveness of different policies across different countries. We assessed the cost-effectiveness of five tobacco control policies (nonschool bans, including bans on sales to minors, bans on smoking in public places, bans on advertising at points-of-sale, school smoke-free bans, and school education programs), implemented in 2016 in Finland, Ireland, the Netherlands, Belgium, Germany, Italy, and Portugal.

methodsCost-effectiveness estimates were calculated per country and per policy, from the State perspective. Costs were collected by combining quantitative questionnaires with semi-structured interviews on how policies were implemented in each setting, in real practice. Short-term effectiveness was based on the literature, and long-term effectiveness was modeled using the DYNAMO-HIA tool. Discount rates of 3.5% were used for costs and effectiveness. Sensitivity analyses considered 1%-50% short-term effectiveness estimates, highest cost estimates, and undiscounted effectiveness.

findingsNonschool bans cost up to €253.23 per healthy life year, school smoking bans up to €91.87 per healthy life year, and school education programs up to €481.35 per healthy life year. Cost-effectiveness depended on the costs of implementation, short-term effectiveness, initial smoking rates, dimension of the target population, and weight of smoking in overall mortality and morbidity.

conclusionsAll five policies were highly cost-effective in all countries according to the World Health Organization thresholds for public health interventions. Cost-effectiveness was preserved even when using the highest costs and most conservative effectiveness estimates. IMPLICATIONS: Economic evaluations using real-world data on tobacco control policies implemented at a large scale are scarce, especially considering nonschool bans targeting adolescents. We assessed the cost-effectiveness of five tobacco control policies implemented in 2016 in Finland, Ireland, the Netherlands, Belgium, Germany, Italy, and Portugal. This study shows that all five policies were highly cost-effective considering the World Health Organization threshold, even when considering the highest costs and most conservative effectiveness estimates.

Indexed as

Cost-Benefit AnalysisAdolescentBelgiumEuropeFemaleFinlandGermanyHealth PolicyHealth PromotionHumansIrelandItalyMaleNetherlandsPortugalSmoke-Free Policy

Identifiers

PMID31350556
PMCPMC7291799
OpenAlexW2964474687

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.